

# Christina Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/441498/publications.pdf>

Version: 2024-02-01

42  
papers

696  
citations

567281

15  
h-index

610901

24  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1085  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncology</i> , 2022, 100, 131-139.	1.9	5
2	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
3	Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. <i>Oncologist</i> , 2022, 27, 740-750.	3.7	2
4	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , 2021, 36, 120-129.	1.6	7
5	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , 2021, 123, 596-605.	1.7	3
6	Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 95-95.	1.6	5
7	Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.. <i>Journal of Clinical Oncology</i> , 2021, 39, 35-35.	1.6	2
8	Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 89-89.	1.6	0
9	Impact of high-risk features for stage II adenocarcinoma of the appendix. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100329.	1.7	1
10	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , 2021, 11, 592351.	2.8	9
11	Survival Outcomes of Acinar Cell Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 529-536.	1.1	1
12	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 153-160.	2.3	3
13	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	4.2	16
14	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 74-81.	1.3	36
15	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 755113.	2.8	7
16	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 1382-1391.	1.1	2
17	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. <i>Frontiers in Oncology</i> , 2021, 11, 728076.	2.8	10
18	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 660-667.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2020, 121, 294-302.	1.7	8
20	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , 2020, 126, 4136-4147.	4.1	6
21	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	6.4	6
22	Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. <i>Cancer</i> , 2020, 126, 3360-3371.	4.1	18
23	Young Adults With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 341-354.	1.1	12
24	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	7.0	9
25	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829.	1.1	2
26	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	3.7	30
27	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020, 25, 414-421.	3.7	11
28	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3117-3125.	7.0	13
29	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 1749-1757.	1.8	29
30	&lt;p&gt;Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	3.7	15
31	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618.	1.9	26
32	Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team. <i>Journal of Surgical Oncology</i> , 2019, 120, 1365-1370.	1.7	19
33	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	4.1	19
34	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268.	2.3	24
35	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920.	3.7	39
36	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67.	4.1	15

#	ARTICLE	IF	CITATIONS
37	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	4.1	17
38	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711.	3.7	15
39	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	5.9	37
40	Systemic Therapy for Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 235-242.	1.5	113
41	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94.	1.4	24
42	Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. <i>Cancer Letters</i> , 2017, 402, 110-116.	7.2	19